Trial Profile
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 30 Dec 2023 to 30 Mar 2024.
- 29 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Mar 2024.
- 24 Oct 2023 Status changed from suspended to active, no longer recruiting.